Education
About Us
Working with TipRanks
Follow Us
Metagenomi, Inc. (MGX)
NASDAQ:MGX
MGX Stock Chart & Stats
$2.85
-$0.33(-10.00%)
At close: 4:00 PM EST
$2.85
-$0.33(-10.00%)
Day’s Range― - ―
52-Week Range$1.23 - $4.92
Previous CloseN/A
Volume382.73K
Average Volume (3M)639.57K
Market Cap
$107.34M
Enterprise Value-$107.01M
Total Cash (Recent Filing)$204.99M
Total Debt (Recent Filing)$42.99M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 12, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding37,533,134
10 Day Avg. Volume894,143
30 Day Avg. Volume639,568
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.00
Enterprise Value/Revenue-3.17
Enterprise Value/Gross Profit-3.17
Enterprise Value/Ebitda1.24
Forecast
1Y Price Target
$9.00Price Target Upside215.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Gene Editing SuccessMetagenomi's gene editing approach achieved durable FVIII levels over a 19-month horizon in Hemophilia A.
Partnership DevelopmentsMetagenomi continues to guide to the selection of at least one development candidate from its cardiometabolic partnership with Ionis in 2025.
Stock ValuationMGX trades significantly below cash, providing plenty of upside potential with little near-term downside risk.
Bears Say
Clinical Advancement RisksRisks include delays in advancing pipeline candidates, failure to generate favorable clinical data, and possible long-term dilution risk.
Financial ChallengesMGX reported a Q2 net loss of $19.9MM, pointing to financial challenges.
MGX FAQ
What was Metagenomi, Inc.’s price range in the past 12 months?
Metagenomi, Inc. lowest stock price was $1.23 and its highest was $4.92 in the past 12 months.
What is Metagenomi, Inc.’s market cap?
Metagenomi, Inc.’s market cap is $107.34M.
When is Metagenomi, Inc.’s upcoming earnings report date?
Metagenomi, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 28 days.
How were Metagenomi, Inc.’s earnings last quarter?
Metagenomi, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.619 by $0.079.
Is Metagenomi, Inc. overvalued?
According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued.
Does Metagenomi, Inc. pay dividends?
Metagenomi, Inc. does not currently pay dividends.
What is Metagenomi, Inc.’s EPS estimate?
Metagenomi, Inc.’s EPS estimate is -0.58.
How many shares outstanding does Metagenomi, Inc. have?
Metagenomi, Inc. has 37,533,134 shares outstanding.
What happened to Metagenomi, Inc.’s price movement after its last earnings report?
Metagenomi, Inc. reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.619. Following the earnings report the stock price went up 3.191%.
Which hedge fund is a major shareholder of Metagenomi, Inc.?
Currently, no hedge funds are holding shares in MGX
Metagenomi, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (215.79% Upside)
$9.00 (215.79% Upside)
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.40%
12-Months-Change
Fundamentals
Return on Equity
-37.45%
Trailing 12-Months
Asset Growth
-29.44%
Trailing 12-Months
Company Description
Metagenomi, Inc.
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
MGX Stock 12 Month Forecast
Average Price Target
$9.00
▲(215.79% Upside)
Technical Analysis
Oramed Pharm
―
Immunic
―
Atara Biotherapeutics
―
Werewolf Therapeutics
―
Context Therapeutics
―
Ownership Overview
8.08% Insiders
5.79% Mutual Funds
9.28% Other Institutional Investors
73.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---